Evaluation of the role of the UGT1A1 and DPYD genes in the adverse effects of chemotherapy treatments that use irinotecan and/or fluoropyrimidines

• Grant number: 22/00504-8
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: April 01, 2022
• End date: March 31, 2024
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Maria Del Pilar Estevez Diz
• Grantee: Vinícius Humberto Bandeira Cereser
• Host Institution: Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira (ICESP). Coordenadoria de Serviços de Saúde (CSS). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

Adverse drug reactions represent a major negative impact on Medicine both at the individual level and at the health system level, justifying dose changes or even a complete interruption in the use of a drug. Pharmacogenetics seeks to use information about the genetic bases that impact patients' response to drugs and use them to customize treatments in order to maximize therapeutic benefits while reducing adverse reactions. Currently, there are already some guidelines to assist the selection of drugs and doses in clinical practice based on the presence of polymorphisms in genes that modulate their effects. Therefore, following a strategy similar to that adopted in other studies, two pairs of anti-tumor chemotherapeutics and their respective pharmacogenetics of interest will be selected for this project, namely Irinotecan / UGT1A1 and Fluoropyrimidines / DPYD. These pairs will be selected because they have clinical recommendations set out in the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines. The objective of this project is to carry out an analysis of the role of these pairs of chemotherapy drugs and pharmacogenetics in the adverse effects of patients' treatments at the Instituto do Câncer do Estado de São Paulo (ICESP) and to assist in the development of the biobank of the Rede Acadêmica de Pesquisa do Câncer of the Universidade de São Paulo with the material to be collected from the patients. After DNA extraction, this material will be sent to the Instituto Nacional do Câncer (INCA) for genetic analysis and the results will be reported to ICESP for an analysis of the data of patients being treated at ICESP that will be included in the study (100 patients).(AU)